GC1111

recombinant human iduronate-2-sulfatase · Green Cross Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GC1111, covering 2012-02-14 to 2024-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GC1111 in Hunter Syndrom Patients [Phase 3]